九典制药(300705.SZ)获得马来酸曲美布汀片药品注册证书

Core Viewpoint - The company, Jiutian Pharmaceutical, has received the drug registration certificate for Maleate Trimebutine Tablets from the National Medical Products Administration, indicating a significant regulatory approval for a product aimed at treating gastrointestinal disorders [1] Group 1: Product Information - Maleate Trimebutine Tablets are indicated for the treatment of irritable bowel syndrome and gastrointestinal motility disorders, addressing symptoms such as loss of appetite, nausea, vomiting, belching, bloating, abdominal rumbling, abdominal pain, diarrhea, and constipation [1] - The drug was first approved for market release in France in 1970 and is currently available in various forms, including tablets, capsules, and dry mixed suspensions, both domestically and internationally [1]